Drug Profile
Aminolevulinic acid - DUSA
Alternative Names: 5 ALA; 5-Aminolaevulinic acid; 5-Aminolevulinic acid; ALA - DUSA; aminolevulinic acid HCL - DUSA; Delta-aminolevulinic acid; Levulan PDT; Levulan photodynamic therapy; Levulan/Kerastick; Levulan™Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator PARTEQ Innovations
- Developer Cleveland Clinic; DUSA Pharmaceuticals
- Class Amino acids; Antianaemics; Antineoplastics; Diagnostic agents; Imaging agents; Keto acids; Levulinic acids; Nootropics; Skin disorder therapies; Small molecules; Vascular disorder therapies
- Mechanism of Action Antioxidants; Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Actinic keratosis
- Phase II Brain cancer; Skin cancer
- No development reported Barrett's oesophagus; Basal cell nevus syndrome
- Discontinued Acne vulgaris; Leucoplakia; Oesophageal cancer; Photodamage; Psoriasis
Most Recent Events
- 06 Jan 2020 No recent reports on development identified - Phase-II for Basal Cell Nevus Syndrome (In adolescents, In children, In adults) in USA (Topical)
- 26 Dec 2018 DUSA filed a motion for preliminary injunctive relief regarding the patent dispute between DUSA and Biofrontera
- 24 Jul 2018 DUSA Pharmaceuticals files lawsuit againts Biofrontera for patent infringement, trade secret misappropriation and tortious interferance claims for aminolevulinic acid HCl in the US